Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M

Reuters04-01

Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M

Co-Diagnostics posted a net loss of $47 million, compared with a net loss of $38 million a year earlier.
Revenue fell to $0.6 million from $3.9 million, primarily due to lower grant revenue.
Adjusted EBITDA loss narrowed to $28 million from $33.5 million.
Cash, cash equivalents, and marketable investment securities declined to $11.9 million from $29.7 million.
Dwight Egan said Co-Diagnostics is planning an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV, citing reduced COVID prevalence in clinical study locations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603311601PR_NEWS_USPR_____LA23941) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624053748?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 04:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624053748","market":"fut","top_or_hot":-1,"title":"Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Co-Diagnostics posted a net loss of $47 million, compared with a net loss of $38 million a year earlier.\n        </li>\n<li>\n          Revenue fell to $0.6 million from $3.9 million, primarily due to lower grant revenue.\n        </li>\n<li>\n          Adjusted EBITDA loss narrowed to $28 million from $33.5 million.\n        </li>\n<li>\n          Cash, cash equivalents, and marketable investment securities declined to $11.9 million from $29.7 million.\n        </li>\n<li>\n          Dwight Egan said Co-Diagnostics is planning an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV, citing reduced COVID prevalence in clinical study locations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603311601PR_NEWS_USPR_____LA23941) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCo-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 04:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Co-Diagnostics posted a net loss of $47 million, compared with a net loss of $38 million a year earlier.\n        </li>\n<li>\n          Revenue fell to $0.6 million from $3.9 million, primarily due to lower grant revenue.\n        </li>\n<li>\n          Adjusted EBITDA loss narrowed to $28 million from $33.5 million.\n        </li>\n<li>\n          Cash, cash equivalents, and marketable investment securities declined to $11.9 million from $29.7 million.\n        </li>\n<li>\n          Dwight Egan said Co-Diagnostics is planning an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV, citing reduced COVID prevalence in clinical study locations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603311601PR_NEWS_USPR_____LA23941) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CODX","symbol_name":"Co-Diagnostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL94C1SP:1","article_id":"2624053748","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624053748","pubTimestamp":1774987829,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Co-Diagnostics posted a net loss of $47 million, compared with a net loss of $38 million a year earlier.Revenue fell to $0.6 million from $3.9 million, primarily due to lower grant revenue.Adjusted EBITDA loss narrowed to $28 million from $33.5 million.Cash, cash equivalents, and marketable investment securities declined to $11.9 million from $29.7 million.Dwight Egan said Co-Diagnostics is planning an initial FDA 510 submission for an upper respiratory test focused on flu A, flu B, and RSV, citing reduced COVID prevalence in clinical study locations.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CODX":"Co-Diagnostics, Inc.","BK4568":"美国抗疫概念","BK4082":"医疗保健设备"},"translate_title":"Co-Diagnostics 2025财年净亏损扩大至4700万美元；收入降至60万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CODX":0.9},"content_text":"Co-Diagnostics FY25 net loss widens to $47M; revenue drops to $0.6M\n    \n\n\n          Co-Diagnostics posted a net loss of $47 million, compared with a net loss of $38 million a year earlier.\n        \n\n          Revenue fell to $0.6 million from $3.9 million, primarily due to lower grant revenue.\n        \n\n          Adjusted EBITDA loss narrowed to $28 million from $33.5 million.\n        \n\n          Cash, cash equivalents, and marketable investment securities declined to $11.9 million from $29.7 million.\n        \n\n          Dwight Egan said Co-Diagnostics is planning an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV, citing reduced COVID prevalence in clinical study locations.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603311601PR_NEWS_USPR_____LA23941) on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624053748","isCrawlerRequest":true}